Aeglea BioTherapeutics, Inc. (AGLE)

NASDAQ: AGLE · IEX Real-Time Price · USD
12.17
+0.31 (2.61%)
Sep 25, 2023, 9:49 AM EDT - Market open
2.61%
Market Cap 48.45M
Revenue (ttm) 1.23M
Net Income (ttm) -272.56M
Shares Out 4.05M
EPS (ttm) -71.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,974
Open 11.78
Previous Close 11.86
Day's Range 11.78 - 12.17
52-Week Range 2.66 - 39.00
Beta 2.53
Analysts Hold
Price Target 20.00 (+64.34%)
Earnings Date Nov 2, 2023

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline inclu... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2016
Employees 14
Stock Exchange NASDAQ
Ticker Symbol AGLE
Full Company Profile

Financial Performance

In 2022, AGLE's revenue was $2.33 million, a decrease of -87.57% compared to the previous year's $18.74 million. Losses were -$83.82 million, 27.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AGLE stock is "Hold." The 12-month stock price forecast is $20.0, which is an increase of 64.34% from the latest price.

Price Target
$20.0
(64.34% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Aeglea BioTherapeutics to Participate in Upcoming September Conference

WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to tran...

10 days ago - PRNewsWire

Aeglea BioTherapeutics Announces Reverse Stock Split

WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans...

18 days ago - PRNewsWire

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer  Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer...

Other symbols: ARQT
20 days ago - PRNewsWire

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, i...

6 weeks ago - PRNewsWire

Polar Capital Holdings Plc Enters Stake in Aeglea BioTherapeutics Inc

On July 19, 2023, Polar Capital Holdings Plc (Trades, Portfolio), a London-based investment firm, made a significant move in the biotechnology sector by investing in 3,936,198 shares in Aeglea BioTher...

2 months ago - GuruFocus

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Grant of Inducement Awards

AUSTIN, Texas and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, ...

3 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from ...

3 months ago - PRNewsWire

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) toda...

4 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 mil...

7 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of...

9 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas, Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

10 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

AUSTIN, Texas , Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...

10 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative...

11 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficienc...

11 months ago - PRNewsWire

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

Event to be Held Thursday, October 27 th at 10 AM ET AUSTIN, Texas , Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new ...

1 year ago - PRNewsWire

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s...

1 year ago - PRNewsWire

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit pe...

1 year ago - PRNewsWire

Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: PALTASTCOPFI
1 year ago - Benzinga

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Prioritizing  Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO an...

1 year ago - PRNewsWire

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

AUSTIN, Texas , Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peo...

1 year ago - PRNewsWire

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Millio...

1 year ago - PRNewsWire

Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company's Biologics License Application (BLA) with a Refusal to File (RTF) l...

1 year ago - Benzinga

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peo...

1 year ago - PRNewsWire